Squamous Cell Carcinoma Clinical Trials

Researchers want to find the best dose of AZD9592 to use in people with lung and head and neck cancers. They will assess AZD9592 when it is given alone and with the anti-cancer drug osimertinib. The people in this study have advanced non-small cell lung cancer (NSCLC) or head and neck cancer with mutations (changes or variants) in the EGFR gene.

In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.

Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:

Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:

Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).

Doctors routinely use intensity-modulated radiation therapy (IMRT) after surgery to treat squamous cell carcinoma (cancer) of the tongue. IMRT delivers radiation directly to cancer cells from different angles by changing the radiation beam into multiple smaller beams. By targeting the tumor more precisely, IMRT reduces radiation damage to healthy tissue.

Researchers are comparing pembrolizumab given after surgery for head and neck cancer with the usual treatment. The usual therapy includes chemotherapy and radiation therapy. The people in this study have head and neck cancer that came back or is a new primary cancer.

Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Cetuximab binds to a protein called EGFR, which is found on some types of tumor cells. This drug may help keep tumor cells from growing. Pembrolizumab helps the body's immune system attack the tumor and may interfere with tumor growth and spread.